drugset
drugset / Trial / NCT01471093

Safety Study of OPC-12759 Ophthalmic Solution

NCT01471093 ↗

Phase 1 Completed 100 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of OPC-12759 ophthalmic solution in healthy subjects.

Timeline

Start
2011-11
Primary completion
2011-12
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 2 % Other

Indications

dry eye syndrome